entertainment -WSS

entertainment

author：focus 2025-10-02 18:50:15 - browse：61

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： 'Essentially witchcraft:' A former naturopath takes on the field

WSS

Wisconsin governor employs partial veto to fund schools for 4 centuries

Pharma companies must ensure equitable access to obesity drugs

'Essentially witchcraft:' A former naturopath takes on the field

Cigna wins case to block Amy Bricker's move to CVS

The aspartame in Diet Coke probably isn’t giving you cancer

'Essentially witchcraft:' A former naturopath takes on the field

focus

entertainment

explore

How one medical school became remarkably diverse

Lilly's Alzheimer's drug donanemab backed by FDA advisers

In Memoriam: Notable people who died in 2023

The system is set up to fail children with medical complexity

ChatGPT in medicine: STAT answers readers' burning questions

Cigna wins case to block Amy Bricker's move to CVS

Apple is now the first public company to be valued at $3 trillion

Eisai exec who led development of Alzheimer’s drug to retire

Duchenne breakthrough therapy leaves behind pioneering families

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

hotspot

The aspartame in Diet Coke probably isn’t giving you cancer

STAT Virtual Event: ASCO Recap, Live!

STAT Virtual Event: ASCO Recap, Live!

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Report captures long Covid’s disabling effects and policy challenges

Report captures long Covid’s disabling effects and policy challenges

explore

focus

focus

hotspot